Some Good News -- But Again, Largely Immaterial.

[This is just a short Thursday filler-post, with the immortal beloved Jedis to arrive shortly. . . then the Revenge of the Sixth. Grin -- with tacos for Cinco in between.]

Merck saw very encouraging first line results in HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma -- via KEYNOTE-811. Here's that bit:

. . .[Merck announced that] the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. . . .

Onward, the pembrolizumab juggernaut rolls. We will try to get some Q1 '24 updated lobby disclosures out before "The Fourth Be With You". . . smile.

नमस्ते